scispace - formally typeset
J

Jun Zhu

Researcher at Peking Union Medical College

Publications -  247
Citations -  38934

Jun Zhu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 41, co-authored 147 publications receiving 33326 citations. Previous affiliations of Jun Zhu include Cardiovascular Institute of the South & Karolinska Institutet.

Papers
More filters
Journal ArticleDOI

Dabigatran versus warfarin in patients with atrial fibrillation

Stuart J. Connolly, +18 more
- 10 Dec 2009 - 
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Christopher B. Granger, +29 more
- 14 Sep 2011 - 
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Theo Vos, +689 more
- 22 Aug 2015 - 
TL;DR: In the Global Burden of Disease Study 2013 (GBD 2013) as mentioned in this paper, the authors estimated the quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013.
Journal ArticleDOI

Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals

Li Liu, +9 more
- 17 Dec 2016 - 
TL;DR: The annual estimates of child mortality by cause to 2000–15 are updated to reflect on progress toward the MDG 4 and consider implications for the Sustainable Development Goals (SDG) target for child survival.
Journal ArticleDOI

Apixaban in Patients with Atrial Fibrillation

Stuart J. Connolly, +29 more
- 02 Mar 2011 - 
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.